Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 5/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 7/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.41 |
| ▸ | KYNU | Q16719 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084706 | 0.90 | GSTP1 (0.45) | ITGA4ITGB7CTSLHDAC1HDAC2 | |
| SCHEMBL4088783 | 0.89 | GSTP1 (0.44) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL4084378 | 0.87 | CTSL (0.48) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL4094926 | 0.86 | CTSL (0.44) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL4097234 | 0.85 | GSTP1 (0.45) | ITGA4ITGB7CTSLHDAC1HDAC2 | |
| SCHEMBL4089300 | 0.84 | GSTP1 (0.46) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL4100004 | 0.82 | GSTP1 (0.48) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL13774898 | 0.81 | GRM8 (0.56) | ITGA4ITGB7CTSLHDAC1HDAC2 | |
| SCHEMBL4091635 | 0.80 | GSTP1 (0.47) | CTSLHDAC1HDAC2GSTP1GSTM2 | |
| SCHEMBL4094784 | 0.80 | ALDH1A1 (0.47) | CTSLHDAC1HDAC2GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | P4HA1, CYP2R1, EGLN3 | ITGA4 3332/4885ITGB7 3407/4885CTSL 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.